Gene expression of genital human papillomaviruses and considerations on potential antiviral approaches

Antiviral Therapy

Volumn 7, Issue 4, 2002, Pages 219-237

  Bernard, Hans Ulrich ^a,b  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; COMPLEMENTARY RNA; GLUCOCORTICOID; PROGESTERONE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1;

CELL DIFFERENTIATION; CELL KINETICS; CELL SPECIFICITY; CPG ISLAND; DRUG TARGETING; ENHANCER REGION; EPITHELIUM CELL; GENE EXPRESSION; GENE REPLICATION; GENE SEQUENCE; GENE SILENCING; GENETIC CODE; GENETIC RISK; GENETIC TRANSCRIPTION; GENITAL TRACT CANCER; NEGATIVE FEEDBACK; NUCLEOTIDE SEQUENCE; PAPILLOMA VIRUS; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; RISK ASSESSMENT; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SILENCER GENE; TRANSCRIPTION REGULATION; TUMOR GROWTH; VIRUS TRANSCRIPTION; WART VIRUS;

ANTIVIRAL AGENTS; ATTACHMENT SITES, MICROBIOLOGICAL; CPG ISLANDS; DNA METHYLATION; ENHANCER ELEMENTS (GENETICS); ERYTHROID-SPECIFIC DNA-BINDING FACTORS; GENE SILENCING; GENITALIA; HUMANS; NUCLEAR MATRIX; NUCLEOSOMES; PAPILLOMAVIRIDAE; PROMOTER REGIONS (GENETICS); TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; VIRUS REPLICATION;

EID: 0036974954     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. International Agency for Research on Cancer Monograph on the evaluation of carcinogenic risks to humans. Volume 64: Human papillomaviruses. IARC, Lyon, France 1995.
2. zur Hausen H. Papillomavirus infections - a major cause of human cancers. Biochimica and Biophysica Acta 1996; 1288:F55-F78.
3. Howley PM. Papillomavirinae: the viruses and their replication. In Fields Virology; 1996. Edited by BN Fields, DM Knipe & PM Howley. Philadelphia: Lippincott-Raven Publ.
4. Chan SY, Delius H, Halpern AL & Bernard HU. Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy. Journal of Virology 1995; 69:3074-3083.
5. Hampsey M & Reinberg D. RNA polymerase II as a control panel for multiple coactivator complexes. Current Opinion on Genes Development 1999; 9:132-139.
6. Lowy DR, Dvoretzky I, Shober R, Law MF, Engel L, Howley PM. In vitro tumorigenic transformation by a defined sub-genomic fragment of bovine papilloma virus DNA. Nature 1980; 287:72-74.
7. McBride AA, Romanczuk H, Howley PM. The papillomavirus E2 regulatory proteins. Journal of Biological Chemistry 1991; 266:18411-18414.
8. Ozbun MA & Meyers C. Characterization of late gene transcripts expressed during vegetative replication of human papillomavirus type 31b. Journal of Virology 1997; 71:5161-5172.
9. Ozbun MA & Meyers C. Temporal usage of multiple promoters during the life cycle of human papillomavirus type 31b. Journal of Virology 1998; 72:2715-2722.
10. Baker CC & Calef C. Maps of papillomavirus transcripts. In Human papillomaviruses, 1995 Compendium. Edited by G Myers, HU Bernard, H Delius, C Baker, J Icenogle, A Halpern & C Wheeler. Los Alamos National Laboratory, Los Alamos, New Mexico, USA, Part III-A, pp. 3-19. Accessible through http://hpv-web.lanl.gov/
11. Smotkin D & Wettstein FO. Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein. Proceeding of the National Academy of Sciences of the USA 1986; 83:4680-4684.
12. Gloss B & Bernard HU. The E6/E7 promoter of human papillomavirus type 16 is activated in the absence of E2 proteins by a sequence-aberrant Sp1 distal element. Journal of Virology 1990; 64:5577-5584.
13. Tan SH, Gloss B & Bernard HU. The viral E2 protein displaces Sp1 from a proximal promoter element during negative regulation of the human papillomavirus-16 E6 promoter. Nucleic Acids Research 1992; 20:251-256.
14. Tan SH, Leong LEC, Walker PA & Bernard HU. The human papillomavirus type 16 transcription factor E2 binds with low cooperativity to two flanking binding sites and represses the E6 promoter through displacement of Sp1 and TFIID. Journal of Virology 1994; 68:6411-6420.
15. Dong G, Broker TR & Chow LT. Human papillomavirus type 11 E2 proteins repress the homologous E6 promoter by interfering with the binding of host transcription factors to adjacent elements. Journal of Virology 1994; 68:1115-1127.
16. Demeret C, Desaintes C, Yaniv M & Thierry F. Different mechanisms contribute to the E2-mediated transcriptional repression of human papillomavirus type 18 viral oncogenes. Journal of Virology 1997; 71:9343-9349.
17. Apt D, Watts, RM, Suske G & Bernard HU. High Sp1/Sp3 ratios in epithelial cells during epithelial differentiation and cellular transformation correlate with the activation of the HPV-16 promoter. Virology 1996; 224:281-291.
18. Stubenrauch F, Hummel M, Iftner T & Laimins LA. The E8E2C protein, a negative regulator of viral transcription and replication, is required for extrachromosomal maintenance of human papillomavirus type 31 in keratinocytes Journal of Virology 2000; 74:1178-1186.
19. Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A & zur Hausen H. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 1985; 314:111-114.
20. Daniel B, Mukherjee G, Seshadri L, Vallikad E & Krishna S. Changes in the physical state and expression of human papillomavirus type 16 in the progression of cervical intraepithelial neoplasia lesions analysed by PCR. Journal of General Virology 1995; 76:2589-2593.
21. Francis DA, Schmid SI & Howley PM. Repression of the integrated papillomavirus E6/E7 promoter is required for growth suppression of cervical cancer cells. Journal of Virology 2000; 74:2679-2686.
22. Gloss B, Bernard HU, Seedorf K & Klock G. The upstream regulatory region of the human papillomavirus-16 contains an E2 protein independent enhancer which is specific for cervical carcinoma cells and regulated by glucocorticoid hormones. EMBO Journal 1987; 6:3735-3743.
23. Cripe TP, Haugen TH, Turk JP, Tabatabai F, Schmid PG, Dürst M, Gissmann L, Roman A & Turek LP. Transcriptional regulation of the human papillomavirus-16 E6-E7 promoter by a keratinocyte-dependent enhancer, and by viral E2 trans-activator and repressor gene products: implications for cervical carcinogenesis. EMBO Journal 1987; 6:3745-3753.
24. Swift FV, Bhat K, Younghusband HB & Hamada H. Characterization of a cell type-specific enhancer found in the human papilloma virus type 18 genome. EMBO Journal 1987; 6:1339-1344.
25. Dollard SC, Broker TR & Chow LT. Regulation of the human papillomavirus type 11 E6 promoter by viral and host transcription factors in primary human keratinocytes. Journal of Virology 1993; 67:1721-1726.
26. Quinlan RA, Schiller DL, Hatzfeld M, Achtstatter T, Moll R, Jorcano JL, Magin TM & Franke WW. Patterns of expression and organization of cytokeratin intermediate filaments. Annals of the New York Academy of Science 1985; 455:282-306.
27. Sailaja G, Watts RM & Bernard HU. Many different papillomaviruses have low transcriptional activity in spite of strong epithelial specific enhancers. Journal of General Virology 1999; 80:1715-1724.
28. Andersen B, Hariri A, Pittelkow MR & Rosenfeld MG. Characterization of Skn-la/i POU domain factors and linkage to papillomavirus gene expression. Journal of Biological Chemistry 1997; 272:15905-15913.
29. Yukawa K, Butz K, Yasui T, Kikutani H & Hoppe-Seyler F. Regulation of human papillomavirus transcription by the differentiation-dependent epithelial factor Epoc-1/skn-1a. Journal of Virology 1996; 70:10-16.
30. Chinenov Y & Kerppola TK. Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene 2001; 20:2438-2452.
31. Gloss B, Chong T & Bernard HU. Numerous nuclear proteins bind the long control region of human papillomavirus type 16: a subset of 6 of 23 DNAseI-protected segments coincides with the location of the cell-type-specific enhancer. Journal of Virology 1988; 63:1142-1152.
32. Chan WK, Chong T, Bernard HU & Klock G. Two AP1 sites in the long control region of human papillomavirus type 16 lead to phorbolester stimulation of the viral E6/E7 promoter. Nucleic Acids Research 1990; 18:763-769.
33. Chong T, Chan WK & Bernard HU. Cooperative activation of the enhancer of human papillomavirus 16 by nuclear factor I, AP1, steroid receptors and a possibly novel transcription factor, PVF: a model for the composition of genital papillomavirus enhancers. Nucleic Acids Research 1990; 18:465-470.
34. Chong T, Apt D, Gloss B, Isa M & Bernard HU. The enhancer of human papillomavirus-16: binding sites for the ubiquitous transcription factors oct-1, NFA, TEF-2, NFI and AP1 participate in the epithelial specific transcription. Journal of Virology 1991; 65:5933-5943.
35. Garcia-Carranca A, Thierry F & Yaniv M. Interplay of viral and cellular proteins along the long control region of human papillomavirus type 18. Journal of Virology 1988; 62:4321-4330.
36. Zhao W, Chow LT & Broker TR. Transcription activities of human papillomavirus type 11 E6 promoter-proximal elements in raft and submerged cultures of foreskin keratinocytes. Journal of Virology 1997; 71:8832-8840.
37. Parker JN, Zhao W, Askins KJ, Broker TR & Chow LT. Mutational analysis of differentiation-dependent human papillomavirus type-18 enhancer elements in epithelial raft cultures of neonatal foreskin keratinocytes. Cell Growth Differentiation 1997; 8:751-762.
38. Butz K & Hoppe-Seyler F. Transcriptional control of human papillomavirus (HPV) oncogene expression: composition of the HPV type 18 upstream regulatory region. Journal of Virology 1993; 67:6476-6486.
39. Lu B, Rothnagel JA, Longley MA, Tsai SY & Roop DR. Differentiation-specific expression of human keratin 1 is mediated by a composite AP-1/steroid hormone element. Journal of Biological Chemistry 1994; 269:7443-7449.
40. Sinha S, Degenstein L, Copenhaver C & Fuchs E. Defining the regulatory factors required for epidermal gene expression. Molecular and Cellular Biology 2000, 20:2543-2555.
41. Rhodes K & Oshima RG. A regulatory element of the human keratin 18 gene with AP-1-dependent promoter activity. Journal of Biological Chemistry 1998; 273:26534-26542.
42. O'Connor M, Chan SY & Bernard HU. Transcription factor binding sites in the long control regions of genital HPVs. In Human papillomaviruses 1995 Compendium. Edited by G Myers, HU Bernard, H Delius, C Baker, J Icenogle, A Halpern, C Wheeler. Los Alamos National Laboratory, Los Alamos, New Mexico, USA, Part III-A, p.21-40. Accessible through http://hpv-web.lanl.gov/
43. Angel P, Szabowski A & Schorpp-Kistner M. Function and regulation of AP-1 subunits in skin physiology and pathology. Oncogene 2001; 20:2413-2423.
44. Thierry F, Spyrou G, Yaniv M & Howley PM. Two AP1 sites binding jun B are essential for human papillomavirus type 18 transcription in keratinocytes. Journal of Virology 1992; 66:3740-3748.
45. Bouallaga I, Massicard S, Yaniv M & Thierry F. An enhanceosome containing the Jun B/Fra-2 heterodimer and the HMG-I(Y) architectural protein controls HPV 18 transcription. EMBO Reports 2000; 1:422-427.
46. Gloss B, Yeo-Gloss M, Meisterernst M, Rogge L, Winnacker EL & Bernard HU. Clusters of nuclear factor I binding sites identify enhancers of several papillomaviruses but alone are not sufficient for enhancer function. Nucleic Acids Research 1989; 17:3519-3533.
47. Leegwater PA, van Driel W & van der Vliet PC. Recognition site of nuclear factor I, a sequence-specific DNA-binding protein from HeLa cells that stimulates adenovirus DNA replication. EMBO Journal 1985; 4:1515-1521.
48. Apt D, Chong T, Liu Y & Bernard HU. Nuclear factor I and epithelial cell-specific transcription of human papillomavirus type 16. Journal of Virology 1993; 67:4455-4463.
49. Apt D, Liu Y & Bernard HU. Cloning and functional analysis of spliced isoforms of human nuclear factor I-X: interference with transcriptional activation by NFI/CTF in a celltype specific manner. Nucleic Acids Research 1994; 22:3825-3833.
50. Ishiji T, Lace MJ., Parkkinen S, Anderson RD, Haugen TH, Cripe TP, Xiao JH, Davidson I, Chambon P & Turek LP. Transcriptional enhancer factor (TEF)-1 and its cell-specific co-activator activate human papillomavirus-16 E6 and E7 oncogene transcription in keratinocytes and cervical carcinoma cells. EMBO Journal 1992; 11:2271-2281.
51. O'Connor M & Bernard HU. Oct-1 activates the epithelial specific enhancer of human papillomavirus type 16 via a synergistic interaction with NFI at a conserved composite regulatory element. Virology 1995; 207:77-88.
52. Sibbet GJ, Cuthill S & Campo MS.The enhancer in the long control region of human papillomavirus type 16 is upregulated by PEF-1 and down-regulated by Oct-1. Journal of Virology 1995; 69:4006-4011.
53. Ndisang D, Budhram-Mahadeo V & Latchman DS. The Brn-3a transcription factor plays a critical role in regulating human papilloma virus gene expression and determining the growth characteristics of cervical cancer cells. Journal of Biological Chemistry 1999; 274:28521-28527.
54. Kyo S, Inoue M, Nishio Y, Nakanishi K, Akira S, Inoue H, Yutsudo M, Tanizawa O & Hakura A. NF-IL6 represses early gene expression of human papillomavirus type 16 through binding to the noncoding region. Journal of Virology 1993; 67:1058-1066.
55. Mack DH & Laimins LA. A keratinocyte-specific transcription factor, KRF-1, interacts with AP-1 to activate expression of human papillomavirus type 18 in squamous epithelial cells. Proceedings of the National Academy of Science USA 1991; 88:9102-9106.
56. Chan WK, Klock G & Bernard HU. Progesterone and glucocorticoid response elements occur in the long control regions of several human papillomaviruses involved in anogenital neoplasia. Journal of Virology 1989; 63:3261-3269.
57. Pater MM, Hughes GA, Hyslop DE, Nakshatri H & Pater A. Glucocorticoid-dependent oncogenic transformation by type 16 but not type 11 human papilloma virus DNA. Nature 1998; 335:832-835.
58. Schiffman MH & Brinton LA. The epidemiology of cervical carcinogenesis. Cancer 1995; 76:1888-1901.
59. Bauknecht T, Angel P, Royer HD & zur Hausen H. Identification of a negative regulatory domain in the human papillomavirus type 18 promoter: interactin with the transcriptional repressor YY1. EMBO Journal 1992; 11:4607-4617.
60. May M, Dong XP, Beyer-Finkler E, Stubenrauch F, Fuchs PG & Pfister H. The E6/E7 promoter of extrachromosomal HPV16 DNA in cervical cancers escapes from cellular repression by mutation of target sequences for YY1. EMBO Journal 1994; 13:1460-1466.
61. O'Connor MJ, Tan SH, Tan CH & Bernard HU. YY1 represses human papillomavirus type 16 transcription by quenching AP-1 activity. Journal of Virology 1996; 70:6529-6539.
62. Galvin KM & Shi Y. Multiple mechanisms of transcriptional repression by YY1. Molecular & Cellular Biology 1997; 17:3723-3732.
63. Chen G & Stenlund A. The E1 initiator recognizes multiple overlapping sites in the papillomavirus origin of DNA replication. Journal of Virology 2001; 75:292-302.
64. O'Connor MJ, Stünkel W, Zimmermann H, Koh CH & Bernard HU. A novel YY1-independent silencer represses the activity of the human papillomavirus type 16 enhancer. Journal of Virology 1998; 72:10083-10092.
65. O'Connor MJ, Stünkel W, Koh CH, Zimmermann H & Bernard HU. The differentiation-specific factor CDP/Cut represses transcription and replication of human papillomaviruses. Journal of Virology 2000; 74:401-410.
66. Ai W, Toussaint E & Roman A. CCAAT displacement protein binds to and negatively regulates human papillomavirus type 6 E6, E7, and E1 promoters. Journal of Virology 1999; 73:4220-4229.
67. Barberis A, Superti-Furga G & Busslinger M. Mutually exclusive interaction of the CCAAT-binding factor and of a displacement protein with overlapping sequences of a histone gene promoter. Cell 1987; 50:347-359.
68. Aufiero B, Neufeld EJ & Orkin SH. Sequence-specific DNA binding of individual cut repeat of the human CCAAT displacement/cut homeodomain protein. Proceedings of the National Academy of Sciences USA 1994; 91:7757-7761.
69. Mailly F, Berube G, Harada R, Mao PL, Phillips S & Nepveu A. The human cut homeodomain protein can repress gene expression by two distinct mechanisms: active repression and competition for binding site occupancy. Molecular & Cell Biology 1996; 16:5346-5357.
70. Skalnik DG, Strauss EC & Orkin SH. CCAAT displacement protein as a repressor of the myelomonocytic-specific gp91-phox gene promoter. Journal of Biological Chemistry 1991; 266:16736-16744.
71. Li S, Moy L, Pittman N, Shue G, Aufiero B, Neufeld EJ, LeLeiko NS & Walsh MJ. Transcriptional repression of the cystic fibrosis transmembrane conductance regulator gene, mediated by CCAAT displacement protein/cut homolog, is associated with histone deacetylation. Journal of Biological Chemistry 1999; 274:7803-7815.
72. Wolffe A & Hayes JJ. Chromatin disruption and modification. Nucleic Acids Research 1999; 27:711-720.
73. Stünkel W & Bernard HU. The chromatin structure of the long control region of human papillomavirus type 16 represses viral oncoprotein expression. Journal of Virology 1999; 73:1918-1930.
74. Yao YL, Yang WM & Seto E. Regulation of transcription factor YY1 by acetylation and deacetylation. Molecular & Cell Biology 2001; 21:5979-5991.
75. Pattison S, Skalnik DG & Roman A. CCAAT displacement protein, a regulator of differentiation-specific gene expression, binds a negative regulatory element within the 5′ end of the human papillomavirus type 6 long control region. Journal of Virology 1997; 71:2013-2022.
76. Zhao W, Noya F, Chen WY, Townes TM, Chow LT & Broker TR. Trichostatin A up-regulates human papillomavirus type 11 upstream regulatory region-E6 promoter activity in undifferentiated primary human keratinocytes. Journal of Virology 1999; 73:5026-5033.
77. Bannister AJ & Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature 1996; 384:641-643.
78. Berezney R, Mortillaro MJ, Ma H, Wei X & Samarabandu J. The nuclear matrix: a structural milieu for nuclear genomic function. International Reviews of Cytology 1995; 162A:1-65.
79. Nickerson J, Krockmalnic G, Wan KM & Penman S. The nuclear matrix revealed by eluting chromatin from a crosslinked nucleus. Proceedings of the National Acadademy of Sciences USA 1997; 94:4446-4450.
80. Wei X, Samarabandu J, Devdhar RS, Siegel AJ, Acharya R & Berezney R. Segregation of transcription and replication sites into higher order domains. Science 1998; 281:1502-1506.
81. Tan SH, Bartsch D, Schwartz E & Bernard HU. Nuclear matrix attachment regions of human papillomavirus type 16 point toward conservation of these genomic elements in all genital papillomaviruses. Journal of Virology 1998; 72:3610-3622.
82. Stünkel W, Huang Z, Tan SH, O'Connor M & Bernard HU. Nuclear matrix attachment regions of human papillomavirus-16 repress or activate the E6 promoter depending on the physical state of the viral DNA. Journal of Virology 2000; 74:2489-2501.
83. Kalantari M, Blennow E, Hagmar B & Johansson B. Physical state of HPV16 and chromosomal mapping of the integrated form in cervical carcinomas. Diagnostic Molecular Pathology 2001; 10:46-54.
84. Bode J, Stengert-Iber M, May V, Schlake T & Dietz-Pfeilstetter A. Scaffold/Matrix-attached regions: topological switches with multiple regulatory functions. Critical Reviews on Eukaryotic Gene Expression 1996; 6:115-138.
85. Forrester WC, Genderen CV, Jenuwein T & Grosschedl R. Dependence of enhancer-mediated transcription of the immunoglobulin mu gene on nuclear matrix attachment regions. Science 1994; 265:1221-1225.
86. Forrester WC, Fernandez LA, Grosschedl R. Nuclear matrix attachment regions antagonize methylation-dependent repression of long-range enhancer-promoter interactions. Genes & Development 1999; 13:3003-3014.
87. Gasser SM & Laemmli, UK. Cohabitation of scaffold binding regions with upstream/enhancer elements of three developmentally regulated genes of D. melanogaster. Cell 1986; 46:521-530.
88. Tan TM, Gloss B, Bernard HU & Ting RC. Mechanism of translation of the bicistronic mRNA encoding human papillomavirus type 16 E6-E7 genes. Journal of General Virology 1994; 75:2663-2670.
89. Baker CC. Post-transcriptional regulation of papillomavirus gene expression. In Human papillomaviruses 1997, III 11-16. Eds. Myers G, Baker, C, Münger K, Sverdrup F, McBride A & Bernard HU. Los Alamos National Laboratory, USA. Accessible through http://hpv-web.lanl.gov/
90. Stacey SN, Jordan D, Snijders PJ, Mackett M, Walboomers JM & Arrand JR. Translation of the human papillomavirus type 16 E7 oncoprotein from bicistronic mRNA is independent of splicing events within the E6 open reading frame. Journal of Virology 1995; 69:7023-7031.
91. Rapp B, Pawellek A, Kraetzer F, Schaefer M, May C, Purdie K, Grassmann K & Iftner T. Cell-type-specific separate regulation of the E6 and E7 promoters of human papillomavirus type 6a by the viral transcription factor E2. Journal of Virology 1997; 71:6956-6966.
92. DiLorenzo TP & Steinberg BM. Differential regulation of human papillomavirus type 6 and 11 early promoters in cultured cells derived from laryngeal papillomas. Journal of Virology 1995; 69:6865-6872.
93. Ai W, Narahari J & Roman A. Yin yang 1 negatively regulates the differentiation-specific E1 promoter of human papillomavirus type 6. Journal of Virology 2000; 74:5198-5205.
94. Doorbar J, Foo C, Coleman N, Medcalf L, Hartley O, Prospero T, Napthine S, Sterling J, Winter G & Griffin H. Characterization of events during the late stages of HPV16 infection in vivo using high-affinity synthetic Fabs to E4. Virology 1997; 238:40-52.
95. Baker CC & Howley PM. Differential promoter utilization by the bovine papillomavirus in transformed cells and productively infected wart tissues. EMBO Journal 1987; 6:1027-1035.
96. Stubenrauch F, Leigh IM & Pfister H. E2 represses the late gene promoter of human papillomavirus type 8 at high concentrations by interfering with cellular factors. Journal of Virology 1996; 70:119-126.
97. Ozbun MA & Meyers C. Two novel promoters in the upstream regulatory region of human papillomavirus type 31b are negatively regulated by epithelial differentiation. Journal of Virology 1999; 73:3505-3510.
98. Grassmann K, Rapp B, Maschek H, Petry KU & Iftner T. Identification of a differentiation-inducible promoter in the E7 open reading frame of human papillomavirus type 16 (HPV-16) in raft cultures of a new cell line containing high copy numbers of episomal HPV-16 DNA. Journal of Virology 1996; 70:2339-2349.
99. Kukimoto I & Kanda T. Displacement of YY1 by differentiation-specific transcription factor hSkn-1a activates the P(670) promoter of human papillomavirus type 16. Journal of Virology 2001; 75:9302-9311.
100. del Mar Pena LM & Laimins LA. Differentiation-dependent chromatin rearrangement coincides with activation of human papillomavirus type 31 late gene expression. Journal of Virology 2001; 75:10005-10013.
101. Jones PA & Takai D. The role of DNA methylation in mammalian epigenetics. Science 2001; 293:1068-1070.
102. List HJ, Patzel V, Zeidler U, Schopen A, Rühl G, Stollwerk J & Klock G. Methylation sensitivity of the enhancer from the human papillomavirus type 16. Journal of Biological Chemistry 1994; 269:11902-11911.
103. Thain A, Jenkins O, Clarke AR & Gaston K. CpG methylation directly inhibits binding of the human papillomavirus type 16 E2 protein to specific DNA sequences. Journal of Virology 1996; 70:7233-7235.
104. Hertz JM, Schell G & Doerfler W. Factors affecting de novo methylation of foreign DNA in mouse embryonic stem cells. Journal of Biological Chemistry 1999; 274:24232-24240.
105. Schiller JT & Lowy DR. Papillomavirus-like particle based vaccines: cervical cancer and beyond. Expert Opinion on Biological Therapy 2001; 1:571-581.
106. Gissmann L, Osen W, Muller M & Jochmus I. Therapeutic vaccines for human papillomaviruses. Intervirology 2001; 44:167-175.
107. Beerheide W, Bernard HU, Tan YJ, Ganesan A, Rice WG & Ting AE. Potential drugs against cervical cancer: zinc-ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein. Journal of the National Cancer Institute 1999; 91:1211-1220.
108. Underwood MR, Shewchuk LM, Hassell AM & Phelp WC. Searching for antiviral drugs for human papillomaviruses. Antiviral Therapy 2000; 5:229-242.
109. Hajduk PJ, Dinges J, Miknis GF, Merlock M, Middleton T, Kempf DJ, Egan DA, Walter KA, Robins TS, Shuker SB, Holzman TF & Fesik SW. NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein. Journal of Medicinal Chemistry 1997; 40:3144-3150.
110. Antson AA, Burns JE, Moroz OV, Scott DJ, Sanders CM, Bronstein IB, Dodson GG, Wilson KS & Maitland NJ. Structure of the intact transactivation domain of the human papillomavirus E2 protein. Nature 2000; 403:805-809.
111. Yasugi T, Vidal M, Sakai H, Howley PM & Benson JD. Two classes of human papillomavirus type 16 E1 mutants suggest pleiotropic conformational constraints affecting E1 multimerization, E2 interaction, and interaction with cellular proteins. Journal of Virology 1997; 71:5942-5951.
112. Emery JG, Ohlstein EH & Jaye M. Therapeutic modulation of transcription factor activity. Trends in Pharmacological Sciences 2001; 22:233-240.
113. Tan TM & Ting RC. In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes. Cancer Research 1995; 55:4599-4605.
114. Piano F, Schetter AJ, Mangone M, Stein L & Kemphues KJ. RNAi analysis of genes expressed in the ovary of Caenorhabditis elegans. Current Biology 2000; 10:1619-1622.
115. Urbach AR & Dervan PB. Toward rules for 1:1 polyamide:DNA recognition. Proceedings of the National Academy of Sciences USA 2001; 98:4343-4348.
116. Beerli RR, Segal DJ, Dreier B. & Barbas CF. Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactvl zinc finger proteins constructed from modular building blocks. Proceedings of the National Academy of Sciences USA 1998; 95:14628-14632.
117. Wagner JA. Technology evaluation: tgDCC-E1A, targeted genetics/MD Anderson. Current Opinion on Molecular Therapies 1999; 1:266-270.
118. http://www.aegis.com/new.ads/1995/AD952306.html